Proof-of-Concept Randomized Trial of the Monoclonal Antibody GSK249320 Versus Placebo in Stroke Patients

Steven C Cramer, Lori A Enney, Colleen K Russell, Monica Simeoni, Thomas R Thompson, Steven C Cramer, Lori A Enney, Colleen K Russell, Monica Simeoni, Thomas R Thompson

Abstract

Background and purpose: One class of poststroke restorative therapy focuses on promoting axon outgrowth by blocking myelin-based inhibitory proteins such as myelin-associated glycoprotein. The purpose of the current study was to extend preclinical and clinical findings of GSK249320, a humanized monoclonal antibody to myelin-associated glycoprotein with disabled Fc region, to explore effects on motor outcomes poststroke.

Methods: In this phase IIb double-blind, randomized, placebo-controlled study, patients at 30 centers with ischemic stroke 24 to 72 hours prior and gait deficits were randomized to 2 IV infusions of GSK249320 or placebo. Primary outcome measure was change in gait velocity from baseline to day 90.

Results: A total of 134 subjects were randomized between May 2013 and July 2014. The 2 groups were overall well matched at baseline. The study was stopped at the prespecified interim analysis because the treatment difference met the predefined futility criteria cutoff; change in gait velocity to day 90 was 0.55±0.46 (mean±SD) in the GSK249320 group and 0.56±0.50 for placebo. Secondary end points including upper extremity function were concordant. The 2 IV infusions of GSK249320 were well tolerated. No neutralizing antibodies to GSK249320 were detected.

Conclusions: GSK249320, within 72 hours of stroke, demonstrated no improvement on gait velocity compared with placebo. Possible reasons include challenges translating findings into humans and no direct evidence that the therapy reached the biological target. The antibody was well tolerated and showed low immunogenicity, findings potentially useful to future studies aiming to use a monoclonal antibody to modify activity in specific biological pathways to improve recovery from stroke.

Clinical trial registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01808261.

Keywords: axon; brain; clinical trial; gait; stroke.

© 2017 The Authors.

Figures

Figure 1.
Figure 1.
CONSORT (Consolidated Standards of Reporting Trials) diagram. ITT indicates intent to treat.
Figure 2.
Figure 2.
Box-and-whisker plots of gait velocity change over time and maximum value for the 2 treatment arms (intent-to-treat group).

References

    1. Cramer SC. Repairing the human brain after stroke. II. Restorative therapies. Ann Neurol. 2008;63:549–560. doi: 10.1002/ana.21412.
    1. Li S, Carmichael ST. Growth-associated gene and protein expression in the region of axonal sprouting in the aged brain after stroke. Neurobiol Dis. 2006;23:362–373. doi: 10.1016/j.nbd.2006.03.011.
    1. Mukhopadhyay G, Doherty P, Walsh FS, Crocker PR, Filbin MT. A novel role for myelin-associated glycoprotein as an inhibitor of axonal regeneration. Neuron. 1994;13:757–767.
    1. Domeniconi M, Filbin MT. Overcoming inhibitors in myelin to promote axonal regeneration. J Neurol Sci. 2005;233:43–47. doi: 10.1016/j.jns.2005.03.023.
    1. Walmsley AR, Mir AK. Targeting the Nogo-A signalling pathway to promote recovery following acute CNS injury. Curr Pharm Des. 2007;13:2470–2484.
    1. Irving EA, Vinson M, Rosin C, Roberts JC, Chapman DM, Facci L, et al. Identification of neuroprotective properties of anti-MAG antibody: a novel approach for the treatment of stroke? J Cereb Blood Flow Metab. 2005;25:98–107. doi: 10.1038/sj.jcbfm.9600011.
    1. Torigoe K, Lundborg G. Selective inhibition of early axonal regeneration by myelin-associated glycoprotein. Exp Neurol. 1998;150:254–262. doi: 10.1006/exnr.1997.6775.
    1. Mears S, Schachner M, Brushart TM. Antibodies to myelin-associated glycoprotein accelerate preferential motor reinnervation. J Peripher Nerv Syst. 2003;8:91–99.
    1. Lee JK, Kim JE, Sivula M, Strittmatter SM. Nogo receptor antagonism promotes stroke recovery by enhancing axonal plasticity. J Neurosci. 2004;24:6209–6217. doi: 10.1523/JNEUROSCI.1643-04.2004.
    1. Cash D, Easton AC, Mesquita M, Beech J, Williams S, Lloyd A, et al. GSK249320, a monoclonal antibody against the axon outgrowth inhibition molecule myelin-associated glycoprotein, improves outcome of rodents with experimental stroke. J Neurol Exp Neurosci. 2016;2:28–33.
    1. Barbay S, Plautz EJ, Zoubina E, Frost SB, Cramer SC, Nudo RJ. Effects of postinfarct myelin-associated glycoprotein antibody treatment on motor recovery and motor map plasticity in squirrel monkeys. Stroke. 2015;46:1620–1625. doi: 10.1161/STROKEAHA.114.008088.
    1. Abila B, Cunningham E, Simeoni M. First-time-in-human study with GSK249320, a myelin-associated glycoprotein inhibitor, in healthy volunteers. Clin Pharmacol Ther. 2013;93:163–169. doi: 10.1038/clpt.2012.227.
    1. Cramer SC, Abila B, Scott NE, Simeoni M, Enney LA MAG111539 Study Investigators. Safety, pharmacokinetics, and pharmacodynamics of escalating repeat doses of GSK249320 in patients with stroke. Stroke. 2013;44:1337–1342. doi: 10.1161/STROKEAHA.111.674366.
    1. Richards C, Malouin F, Dumas F, Tardif D. Gait velocity as an outcome measure of locomotor recovery after stroke. In: Craik R, Oates C, editors. In: Gait Analysis: Theory and Application. St. Louis: Mosby; 1995. pp. 355–364.
    1. Duncan PW, Sullivan KJ, Behrman AL, Azen SP, Wu SS, Nadeau SE, et al. LEAPS Investigative Team. Body-weight-supported treadmill rehabilitation after stroke. N Engl J Med. 2011;364:2026–2036. doi: 10.1056/NEJMoa1010790.
    1. Fritz S, Lusardi M. White paper: “walking speed: the sixth vital sign.”. J Geriatr Phys Ther. 2009;32:46–49.
    1. Tilson JK, Sullivan KJ, Cen SY, Rose DK, Koradia CH, Azen SP, et al. Locomotor Experience Applied Post Stroke (LEAPS) Investigative Team. Meaningful gait speed improvement during the first 60 days poststroke: minimal clinically important difference. Phys Ther. 2010;90:196–208. doi: 10.2522/ptj.20090079.
    1. Winstein CJ, Stein J, Arena R, Bates B, Cherney LR, Cramer SC, et al. American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Quality of Care and Outcomes Research. Guidelines for Adult Stroke Rehabilitation and Recovery: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2016;47:e98–e169. doi: 10.1161/STR.0000000000000098.
    1. Perry J, Garrett M, Gronley JK, Mulroy SJ. Classification of walking handicap in the stroke population. Stroke. 1995;26:982–989.
    1. Cramer SC, Koroshetz WJ, Finklestein SP. The case for modality-specific outcome measures in clinical trials of stroke recovery-promoting agents. Stroke. 2007;38:1393–1395. doi: 10.1161/01.STR.0000260087.67462.80.
    1. Salbach NM, Mayo NE, Higgins J, Ahmed S, Finch LE, Richards CL. Responsiveness and predictability of gait speed and other disability measures in acute stroke. Arch Phys Med Rehabil. 2001;82:1204–1212. doi: 10.1053/apmr.2001.24907.
    1. Bohannon R, Andrews A, Smith M. Rehabilitation goals of patients with hemiplegia. Int J Rehab Research. 1988;11:181–183..
    1. Fisher CM. Lacunar strokes and infarcts: a review. Neurology. 1982;32:871–876.
    1. Pullicino P, Nelson RF, Kendall BE, Marshall J. Small deep infarcts diagnosed on computed tomography. Neurology. 1980;30:1090–1096.
    1. Sprigg N, Gray LJ, Bath PM, Lindenstrøm E, Boysen G, De Deyn PP, et al. TAIST Investigators. Early recovery and functional outcome are related with causal stroke subtype: data from the tinzaparin in acute ischemic stroke trial. J Stroke Cerebrovasc Dis. 2007;16:180–184. doi: 10.1016/j.jstrokecerebrovasdis.2007.02.003.
    1. Kawamata T, Dietrich WD, Schallert T, Gotts JE, Cocke RR, Benowitz LI, et al. Intracisternal basic fibroblast growth factor enhances functional recovery and up-regulates the expression of a molecular marker of neuronal sprouting following focal cerebral infarction. Proc Natl Acad Sci USA. 1997;94:8179–8184.
    1. Duncan PW, Goldstein LB, Matchar D, Divine GW, Feussner J. Measurement of motor recovery after stroke. Outcome assessment and sample size requirements. Stroke. 1992;23:1084–1089.
    1. Dijkhuizen RM, Ren J, Mandeville JB, Wu O, Ozdag FM, Moskowitz MA, et al. Functional magnetic resonance imaging of reorganization in rat brain after stroke. Proc Natl Acad Sci USA. 2001;98:12766–12771. doi: 10.1073/pnas.231235598.
    1. Calautti C, Leroy F, Guincestre JY, Baron JC. Dynamics of motor network overactivation after striatocapsular stroke: a longitudinal PET study using a fixed-performance paradigm. Stroke. 2001;32:2534–2542.
    1. Tombari D, Loubinoux I, Pariente J, Gerdelat A, Albucher JF, Tardy J, et al. A longitudinal fMRI study: in recovering and then in clinically stable sub-cortical stroke patients. Neuroimage. 2004;23:827–839. doi: 10.1016/j.neuroimage.2004.07.058.
    1. Goldberg MP, Ransom BR. New light on white matter. Stroke. 2003;34:330–332.
    1. Cramer SC. Clinical issues in animal models of stroke and rehabilitation. ILAR J. 2003;44:83–84.
    1. Cramer SC. Drugs to Enhance Motor Recovery After Stroke. Stroke. 2015;46:2998–3005. doi: 10.1161/STROKEAHA.115.007433.
    1. Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI, et al. STAIR Group. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke. 2009;40:2244–2250. doi: 10.1161/STROKEAHA.108.541128.
    1. Dirnagl U. Thomas Willis lecture: is translational stroke research broken, and if so, how can we fix it? Stroke. 2016;47:2148–2153. doi: 10.1161/STROKEAHA.116.013244.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa